The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis.
Christopher JacksonLeila FinikaridesAlexandra L J FreemanPublished in: PloS one (2022)
This meta-analysis should allow clinicians and patients to better identify and quantify the potential adverse effects of adding trastuzumab to their treatment regime for breast cancer, and hence inform their decision-making. However, limitations include serious risk of bias due to heterogeneity in reporting of the outcomes and the open-label nature of the trials.
Keyphrases
- systematic review
- end stage renal disease
- open label
- decision making
- epidermal growth factor receptor
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- palliative care
- adverse drug
- squamous cell carcinoma
- single cell
- randomized controlled trial
- study protocol
- radiation therapy
- patient reported outcomes
- insulin resistance
- combination therapy
- phase ii